Blueprint Medicines (NASDAQ:BPMC) Upgraded to “Outperform” at Oppenheimer
Oppenheimer upgraded shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) from a market perform rating to an outperform rating in a report issued on Friday, MarketBeat.com reports. The brokerage currently has $85.00 price objective on the biotechnology company’s stock. Several other research firms have also recently commented on BPMC. StockNews.com initiated coverage on shares of […]
More Stories
Groupama Asset Managment Acquires 3,822 Shares of Northern Trust Co. (NASDAQ:NTRS)
Groupama Asset Managment lifted its holdings in shares of Northern Trust Co. (NASDAQ:NTRS – Free Report) by 113.6% during the...
XTX Topco Ltd Acquires 31,186 Shares of Smith & Nephew plc (NYSE:SNN)
XTX Topco Ltd grew its holdings in shares of Smith & Nephew plc (NYSE:SNN – Free Report) by 302.2% in...
Zacks Investment Management Purchases 994 Shares of Teledyne Technologies Incorporated (NYSE:TDY)
Zacks Investment Management boosted its position in Teledyne Technologies Incorporated (NYSE:TDY – Free Report) by 111.3% in the third quarter,...
Executive Wealth Management LLC Has $7.36 Million Stake in Amdocs Limited (NASDAQ:DOX)
Executive Wealth Management LLC grew its stake in Amdocs Limited (NASDAQ:DOX – Free Report) by 14.2% during the third quarter,...
Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF (NASDAQ:PDBC) Shares Bought by Executive Wealth Management LLC
Executive Wealth Management LLC raised its position in Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF (NASDAQ:PDBC – Free...
Nomura Asset Management Co. Ltd. Purchases 61,941 Shares of Citigroup Inc. (NYSE:C)
Nomura Asset Management Co. Ltd. boosted its position in shares of Citigroup Inc. (NYSE:C – Free Report) by 9.3% in...